Results 61 to 70 of about 79,184 (165)

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak   +2 more
wiley   +1 more source

Cryptococcid Sweet Syndrome in the Setting of Hydralazine‐Induced ANCA Vasculitis: A Case Report

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 4, Page 356-361, April 2026.
ABSTRACT Acute febrile neutrophilic dermatosis, also known as Sweet syndrome, is an inflammatory skin condition characterized by the rapid onset of painful, erythematous plaques or nodules with neutrophilic infiltrate on histology. Rarely, acellular bodies surrounded by vacuolated spaces have been noted within the neutrophilic infiltrate, mimicking ...
Jenna Vroman   +4 more
wiley   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2978-2987, April 2026.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino   +14 more
wiley   +1 more source

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

open access: yesImmunology, Volume 177, Issue 4, Page 736-748, April 2026.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Therapeutic Dilemmas in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Diffuse Alveolar Hemorrhage and Venous Thromboembolism

open access: yesACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Diffuse alveolar hemorrhage (DAH) is a life‐threatening presentation of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Patients with AAV are at an increased risk of venous thromboembolic events (VTEs). These manifestations can co‐occur; however, the prognosis and management of these patients are poorly understood. Methods In
Elif D. Ediboglu   +5 more
wiley   +1 more source

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

open access: yesAdvanced Science, Volume 13, Issue 14, 9 March 2026.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi   +8 more
wiley   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, Volume 78, Issue 3, Page 695-704, March 2026.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair   +14 more
wiley   +1 more source

ANCA Glomerulonephritis and Vasculitis.

open access: yesAmerican Society of Nephrology. Clinical Journal, 2017
J. Charles Jennette, Patrick H. Nachman
semanticscholar   +1 more source

Pediatric Non‐Lupus Full House Nephropathy: Case Report and Review of Literature

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE) typically characterized by glomerular “full‐house” immunofluorescence. However, non‐lupus nephropathies may occasionally exhibit similar patterns, creating diagnostic uncertainty.
Mohammad Firoz Anjum   +4 more
wiley   +1 more source

Unveiling the immune landscape and microenvironmental architecture of IgA nephropathy using single‐cell imaging mass cytometry

open access: yesClinical &Translational Immunology, Volume 15, Issue 3, March 2026.
In IgA nephropathy (IgAN), innate and adaptive immune cells display distinct spatial compartmentalisation, with macrophages predominating within glomeruli and CD4+ T cells constituting the major immune population in inflammatory foci. Glomeruli with distinct pathological morphologies exhibit morphology‐dependent immune infiltration patterns and ...
Xing Chen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy